LongueVue Capital, a New Orleans-based private equity firm, announce that its portfolio company Pinnacle Clinical Research has completed successful investments in five clinical trial sites in Texas, New Jersey and South Carolina. Pinnacle has invested in Kerwin Medical Center (KMC), The Cognitive and Research Center of New Jersey (CRCNJ), Bellaire Clinical Research, Palmetto Clinical Research – Low Country and Dallas Research Institute.
Headquartered in Dallas, Texas and founded in 2019, KMC is a leading clinical research network operating one site in Dallas. The company is currently opening another site in South Dallas.
CRCNJ, headquartered in Springfield, New Jersey, is a central nervous system clinical research site with a focus on Alzheimer’s Disease. CRCNJ currently operates one site in Springfield, New Jersey and is currently opening its second site location in Ridgewood, New Jersey.
Bellaire Clinical Research is a clinical trial site with a focus on metabolic disease and obesity-related clinical trials. Headquartered in Houston, Texas, Bellaire has established a reputation for outperforming enrollments as well as serving disproportionately impacted patient populations.
Palmetto Clinical Research – Low Country is a multidisciplinary clinical site focused on metabolic disease, obesity and central nervous system-related studies. The company is headquartered in Summerville, South Carolina.
Headquartered in Dallas, Texas, Dallas Research Institute is focused on executing complex metabolic clinical trials in underserved communities supporting underrepresented patient populations.
Pinnacle Clinical Research is dedicated to conducting clinical trials in the areas of hepatology and gastroenterology, with a focus on fatty liver disease. The company has announced two transactions in the clinical trial space since it was acquired by LongueVue Capital in November 2022. The company previously merged with South Texas Research Institute in Edinburg, Texas.
Crosstree Capital Partners served as the buyside advisor to LongueVue Capital for both the KMC and CRCNJ transactions. Valcadia Healthcare Partners served as the sellside advisor for CRCNJ. These acquisitions further bolster Pinnacle’s value proposition as a leader across multiple complex therapeutic indications while providing high-quality patient care, superior patient enrollment timelines and access to underrepresented patient populations. Financial terms of the deal were not disclosed.
